Literature DB >> 10466994

Assessment of cardiac risk before aortic reconstruction: noninvasive work-up using clinical examination, exercise testing, and dobutamine stress echocardiography versus routine coronary arteriography.

T Therre1, J P Ribal, P Motreff, J R Lusson, J B Espeut, J Cassagnes, G Glanddier.   

Abstract

In this prospective study we evaluated the efficacy of a battery of noninvasive tests including clinical evaluation (CE), exercise testing (ET), and dobutamine stress echocardiography (DSE) for assessment of cardiac risk in 90 patients indicated for aortic reconstruction. As the gold-standard reference technique, coronary arteriography was performed in each patient after noninvasive evaluation. The sensitivity of CE was low (61%). ET proved to be more sensitive (71.4%) and highly specific (95.8%) but feasibility (77%) and diagnostic accuracy (42%) were low. DSE demonstrated acceptable sensitivity (78%) and specificity (75.5%) with high feasibility (94.5%) and diagnostic accuracy (100%). None of the four patients with false negative ET results and only one of seven with false-negative DSE required coronary bypass. On the basis of these findings we conclude that a combination of CE and ET with DES, if necessary, can reliably assess cardiac risk before aortic reconstruction. Noninvasive assessment is a reliable alternative to routine coronary arteriography.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10466994     DOI: 10.1007/s100169900290

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  2 in total

1.  A meta-analytic comparison of echocardiographic stressors.

Authors:  Yoshinori Noguchi; Shizuko Nagata-Kobayashi; James E Stahl; John B Wong
Journal:  Int J Cardiovasc Imaging       Date:  2005 Apr-Jun       Impact factor: 2.357

2.  Stress echocardiography for the diagnosis of coronary artery disease: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.